Publish time: 2023-11-22 00:00:00
12A-1111215
The human viral vectors for gene therapy suffer from several drawbacks, including poor cell-type specificity and difficulty in large-scale production. The M13 phage provides an alternative vehicle with engineerable specificity and economic production, but the low transduction efficiency seriously limits its translational applications. Here, we presented a breakthrough of utilizing the M13 phage as a gene-delivery vehicle. By shortening the phage length with the restructured origin, we designed “TransPhage”, which reached an unprecedented transduction efficiency (~95%) that is comparable to the AAV vectors. Moreover, we showed that the TransPhage’s tropism was specific to the cells that overexpress the target antigen, whereas AAVs promiscuously infected many cell types. Based on TransPhage, we invented an immunogene therapy, where a membrane-bound fragment crystallizable region was genetically introduced to cancer cells The new immunogene therapy effectively triggered the cancer cell killing by NK cells and suppressed the tumor growths in the mouse xenograft model. 。
- high transduction efficiency
- good cell-type specificity
- economic large production
- lack of existing neutralization antibodies in human
Treatments of cancers or other genetic diseases
Che-Ming Jack Hu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Engineered M13 bacteriophage for gene therapy